SCHEMBL3961837

SCHEMBL3961837

C1COB(B2OCCCO2)OC1

nearest known ligand 0.42

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6240283 0.91 ALDH1A1 (0.36) TSHR
SCHEMBL18292088 0.87 ALDH1A1 (0.33)
SCHEMBL298586 0.80
SCHEMBL23098951 0.72 ALDH1A1 (0.38)
SCHEMBL23098950 0.72
SCHEMBL14832691 0.70
SCHEMBL11510813 0.67
SCHEMBL17787913 0.67
SCHEMBL96591 0.67
SCHEMBL752992 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3303288-B1 PROCESS FOR PREPARING CARBAZOLES DOW GLOBAL TECHNOLOGIES LLC (US) 2021-01-20 EP claimed
US-20080234229-A1 Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders AUSPEX PHARMACEUTICALS, INC. (US) 2008-09-25 US claimed
US-20080221069-A1 Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders AUSPEX PHARMACEUTICALS, INC. (US) 2008-09-11 US claimed
WO-2007028104-A2 NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS AUSPEX PHARMACEUTICALS, INC. (US) 2007-03-08 WO claimed
WO-2007022437-A2 THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND METABOLIC DISORDERS AUSPEX PHARMACEUTICALS, INC. (US) 2007-02-22 WO claimed
EP-4735414-A2 CHEMICALLY DEGRADABLE AND FUNCTIONALLY MODIFIABLE POLYMERS AND HYDROGELS Dana-Farber Cancer Institute, Inc. (US) 2026-05-06 EP disclosed
EP-4622947-A1 ENAMINE N-OXIDE TOOLS FOR TARGET IDENTIFICATION APPLICATIONS Dana-Farber Cancer Institute, Inc. (US) 2025-10-01 EP disclosed
US-20250250233-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE PRILENIA NEUROTHERAPEUTICS LTD. (IL) 2025-08-07 US disclosed
US-20250179004-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. 2025-06-05 US disclosed
WO-2025078494-A1 SYNTHESIS OF EMODEPSIDE VETOQUINOL SA (FR) 2025-04-17 WO disclosed
EP-4538282-A1 SYNTHESIS OF EMODEPSIDE Vetoquinol SA (FR) 2025-04-16 EP disclosed
EP-4519246-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE Prilenia Neurotherapeutics Ltd. (IL) 2025-03-12 EP disclosed
WO-2007028104-A2 NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS AUSPEX PHARMACEUTICALS, INC. (US) 2007-03-08 WO disclosed
EP-1121365-B1 ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS COMMW SCIENT IND RES ORG (AU) 2005-06-08 EP disclosed
EP-1056751-A4 BORONIC COMPOUNDS COMMW SCIENT IND RES ORG (AU) 2003-01-22 EP disclosed
EP-1121365-A4 ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS COMMW SCIENT IND RES ORG (AU) 2002-03-06 EP disclosed
EP-1121365-A1 ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2001-08-08 EP disclosed
EP-1056751-A1 BORONIC COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2000-12-06 EP disclosed
WO-2000021966-A1 ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2000-04-20 WO disclosed
WO-1999033845-A1 BORONIC COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1999-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234229-A1 Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders IGF1R, INSR, BRCA1 TSHR 647/4885
US-20250250233-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE QDPR, MAOB, DRD2 TSHR 890/4885
US-20080221069-A1 Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders GPR119, IGF1R, GCKR TSHR 878/4885
US-20250179004-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS MCL1, BCL3, XIAP TSHR 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.